BioAtla, Inc.
BCABDrugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
BCAB Earnings Report
FQ end 2026-06
CAB-AXL-ADC
Undifferentiated Pleomorphic Sarcoma
BA3071
NSCLC
CAB-ROR2-ADC
Non Small Cell Lung Cancer
Ozuriftamab Vedotin
Head and Neck Cancer
PD-1 inhibitor
Non-Small-Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CAB-AXL-ADC | Phase 2 | Undifferentiated Pleomorphic Sarcoma | - | - |
BA3071 | Phase 2 | NSCLC | - | - |
CAB-ROR2-ADC | Phase 2 | Non Small Cell Lung Cancer | - | - |
Ozuriftamab Vedotin | Phase 2 | Head and Neck Cancer | - | - |
PD-1 inhibitor | Phase 2 | Non-Small-Cell Lung Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BioAtla, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in BioAtla, Inc.'s (BCAB) pipeline across Phase 2. Its lead program is CAB-AXL-ADC (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioAtla, Inc.'s next FDA catalyst?→
BioAtla, Inc.'s (BCAB) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BCAB biotech catalysts?→
Add BCAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioAtla, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.